Quantamental Technologies LLC Buys 2,200 Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA)

Quantamental Technologies LLC boosted its stake in Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 1,100.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,400 shares of the company’s stock after acquiring an additional 2,200 shares during the quarter. Quantamental Technologies LLC’s holdings in Dova Pharmaceuticals were worth $34,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital Investment Advisory Services LLC lifted its position in Dova Pharmaceuticals by 222.2% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock valued at $45,000 after acquiring an additional 2,000 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its position in Dova Pharmaceuticals by 63.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 21,800 shares of the company’s stock valued at $293,000 after acquiring an additional 8,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in Dova Pharmaceuticals in the 2nd quarter valued at $604,000. Spark Investment Management LLC lifted its position in Dova Pharmaceuticals by 31.8% in the 1st quarter. Spark Investment Management LLC now owns 80,500 shares of the company’s stock valued at $715,000 after acquiring an additional 19,400 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Dova Pharmaceuticals by 6.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 67,386 shares of the company’s stock valued at $951,000 after acquiring an additional 3,992 shares in the last quarter. 32.18% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently commented on DOVA shares. Evercore ISI raised shares of Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price objective on the stock in a research report on Monday, July 1st. JPMorgan Chase & Co. boosted their price objective on shares of Dova Pharmaceuticals from $13.00 to $15.00 and gave the company an “underweight” rating in a research report on Friday, July 12th. HC Wainwright boosted their price objective on shares of Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Oppenheimer started coverage on shares of Dova Pharmaceuticals in a research report on Thursday, August 29th. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $24.57.

In other news, insider Jason Hoitt sold 2,387 shares of the business’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $13.81, for a total transaction of $32,964.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO David Zaccardelli sold 10,450 shares of the business’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $15.94, for a total transaction of $166,573.00. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 610,916 shares of company stock worth $8,689,169 and sold 27,807 shares worth $422,464. 60.30% of the stock is currently owned by insiders.

DOVA stock traded up $0.11 during midday trading on Friday, hitting $16.02. The company’s stock had a trading volume of 93,841 shares, compared to its average volume of 175,941. The company has a quick ratio of 5.37, a current ratio of 5.64 and a debt-to-equity ratio of 0.41. Dova Pharmaceuticals Inc has a twelve month low of $5.62 and a twelve month high of $25.09. The company’s fifty day moving average price is $15.36 and its 200 day moving average price is $11.62.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.03). Dova Pharmaceuticals had a negative net margin of 544.09% and a negative return on equity of 101.60%. The business had revenue of $3.52 million during the quarter, compared to analyst estimates of $5.63 million. On average, equities analysts predict that Dova Pharmaceuticals Inc will post -2.43 EPS for the current fiscal year.

Dova Pharmaceuticals Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Featured Story: How to calculate compound interest

Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).

Institutional Ownership by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.